All In Biotech

Drug Trial Radar · NCT06716814

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

A Multinational, Prospective, Open-label, Roll-over Study (LIBERTY) to Provide Post-trial Access to Treatment for Patients With Haemophilia A Who Have Completed a Previous Trial With Efanesoctocog Alfa

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

89

Actual

Start

Mar 6, 2025

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
PSI CRO
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multinational, prospective, open-label, roll-over study in patients with haemophilia A, ≥6 years of age, who have completed participation in any of the parental studies with efanesoctocog alfa; XTEND-ed study (LTS16294), FREEDOM study (Sobi.BIVV001-001), PK comparison study (Sobi.BIVV001-003) or SHINE study (Sobi.BIVV001-004). The aim of the study is to provide patients with continuous benefit from efanesoctocog alfa treatment and to further continue clinical monitoring for safety and efficacy until efanesoctocog alfa is commercially available in each patient's respective country (or until March 2027, whichever comes first). The study starts with the Baseline Visit, which will be done in connection to the end of treatment at the EoT/EoS visit (or equivalent) in the respective parent study. Subsequent study visits (on site or phone call) will be done approximately every 13 weeks until End of Treatment. An End of Study safety phone call will be done 14 (+7) days after the End of Treatment Visit.

Conditions

  • Haemophilia A (Moderate or Severe)

Interventions

  • Efanesoctocog alfaDrug

    Treatment starts when the patient completes the parent study and continues until efanesoctocog alfa is commercially available in each patient's respective country, or until March 2027, whichever comes first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of injections to treat a bleeding episodeTime frame: From enrollment and up to 52 weeks
  2. Total dose to treat a bleeding episodeTime frame: From enrollment and up to 52 weeks
  3. Adverse events (AEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: From enrollment and up to 52 weeks
  4. Annualized bleeding rate (ABR) for treated bleeding episodesTime frame: From enrollment and up to 52 weeks
  5. Annualized bleeding rate (ABR) for treated bleeding episodes by type of bleedTime frame: From enrollment and up to 52 weeks
  6. Annualized bleeding rate (ABR) for treated bleeding episodes by location of bleedTime frame: From enrollment and up to 52 weeks
  7. Annualized bleeding rate (ABR) for all bleeding episodesTime frame: From enrollment and up to 52 weeks
  8. Annualized bleeding rate (ABR) for all bleeding episodes by type of bleedTime frame: From enrollment and up to 52 weeks
  9. Annualized bleeding rate (ABR) for all bleeding episodes by location of bleedTime frame: From enrollment and up to 52 weeks

Locations

20 sites in 7 countries. Site status is shown where the registry gives one.

  • Sobi Investigational Site

    Plovdiv, Bulgaria

  • Sobi Investigational Site

    Sofia, Bulgaria

  • Sobi Investigational Site

    Brest, France

  • Sobi Investigational Site

    Bron, France

  • Sobi Investigational Site

    Lille, France

  • Sobi Investigational Site

    Athens, Greece

  • Sobi Investigational Site

    Catanzaro, Italy

  • Sobi Investigational Site

    Florence, Italy

  • Sobi Investigational Site

    Milan, Italy

  • Sobi Investigational Site

    Naples, Italy

  • Sobi Investigational Site

    Parma, Italy

  • Sobi Investigational Site

    Rome, Italy

  • Sobi Investigational Site

    Rozzano, Italy

  • Sobi Investigational Site

    Vicenza, Italy

  • Sobi Investigational Site

    Oslo, Norway

  • Sobi Investigational Site

    A Coruña, Spain

  • Sobi Investigational Site

    Zaragoza, Spain

  • Sobi Investigational Site

    Gothenburg, Sweden

  • Sobi Investigational Site

    Lund, Sweden

  • Sobi Investigational Site

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.